CompletedPhase 2

Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

Germany14 participantsStarted 2019-11-13

Plain-language summary

The aim of the trial is to improve disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV) for up to one year. The primary objective of the trial is to show efficacy of the experimental consolidative treatment strategy. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with relapsed/refractory cHL who receive an allogeneic stem cell transplantation * Histologically proven cHL in the most recent tumor biopsy * Absolute neutrophil count ≥ 500/mm³ * ECOG ≤2 * Age ≥ 18 years Exclusion Criteria: * Presence of nodular lymphocyte-predominant HL (NLPHL) or grey-zone lymphoma * Progressive disease as last documented response prior to alloSCT * Any peripheral neuropathy ≥ grade 2 * Any other serious disease or organ dysfunction which might impair protocol treatment

What they're measuring

1-year Cumulative incidence of relapse (CIR)

Timeframe: 1 year

Trial details

NCT IDNCT03652441

SponsorUniversity of Cologne

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-08-10

View on ClinicalTrials.gov More Classical Hodgkin Lymphoma trials